DAPA-CKD & EMPA-KIDNEY trials highlight significant absolute risk reductions in renal, cardiovascular, & mortality outcomes with dapagliflozin and empagliflozin. SGLT2 inhibitors continue to transform CKD care across diverse patient populations.
https://t.co/YnyvJIXp1n
The vast majority of patients with #CHD have Lp(a) levels far below what is considered a typical risk-enhancing threshold, suggesting that the attributable risk from Lp(a) is more complex than previously perceived.
Learn more: https://t.co/hrUNOrsUTC #JACC@JACCJournals
@capuzzi_luciano@Irina67790690 By using this method, good correlations with invasively obtained measurements by cardiac catheterization have been shown, in which low velocities across the VSD as well as right-to-left shunting likely indicate PH
@capuzzi_luciano@Irina67790690 In VSDs with left-to-right shunts, the obtained peak Doppler gradient needs to be subtracted from systolic blood pressure (SBP), whereas in right-to-left shunting, it needs to be added to SBP
@capuzzi_luciano@Irina67790690 In the presence of a VSD, sPAP can be estimated through measurement of the maximal velocity across the VSD by CW-Doppler in the absence of RVOT and LV outflow tract (LVOT) obstructions [48].